Annual FCF
-$30.33 M
+$26.33 M+46.47%
December 31, 2023
Summary
- As of February 7, 2025, ALDX annual free cash flow is -$30.33 million, with the most recent change of +$26.33 million (+46.47%) on December 31, 2023.
- During the last 3 years, ALDX annual FCF has risen by +$7.17 million (+19.12%).
- ALDX annual FCF is now -3797.96% below its all-time high of -$778.00 thousand, reached on December 31, 2012.
Performance
ALDX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$7.97 M
+$5.25 M+39.70%
September 30, 2024
Summary
- As of February 7, 2025, ALDX quarterly free cash flow is -$7.97 million, with the most recent change of +$5.25 million (+39.70%) on September 30, 2024.
- Over the past year, ALDX quarterly FCF has increased by +$50.00 thousand (+0.62%).
- ALDX quarterly FCF is now -1693.71% below its all-time high of $500.40 thousand, reached on December 31, 2023.
Performance
ALDX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$30.67 M
+$50.00 K+0.16%
September 30, 2024
Summary
- As of February 7, 2025, ALDX TTM free cash flow is -$30.67 million, with the most recent change of +$50.00 thousand (+0.16%) on September 30, 2024.
- Over the past year, ALDX TTM FCF has increased by +$11.39 million (+27.07%).
- ALDX TTM FCF is now -10192.45% below its all-time high of -$298.00 thousand, reached on March 31, 2013.
Performance
ALDX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ALDX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +46.5% | +0.6% | +27.1% |
| 3 y3 years | +19.1% | +5.4% | +22.0% |
| 5 y5 years | -0.7% | +4.1% | +31.8% |
ALDX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +46.5% | -1693.7% | +60.0% | -1.1% | +46.2% |
| 5 y | 5-year | at high | +46.5% | -1693.7% | +60.0% | -1.1% | +46.2% |
| alltime | all time | -3798.0% | +46.5% | -1693.7% | +60.0% | <-9999.0% | +46.2% |
Aldeyra Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.97 M(-39.7%) | -$30.67 M(-0.2%) |
| Jun 2024 | - | -$13.22 M(+32.6%) | -$30.72 M(-0.4%) |
| Mar 2024 | - | -$9.97 M(-2092.9%) | -$30.86 M(+1.7%) |
| Dec 2023 | -$30.33 M(-46.5%) | $500.40 K(-106.2%) | -$30.33 M(-27.9%) |
| Sep 2023 | - | -$8.02 M(-39.9%) | -$42.06 M(-9.8%) |
| Jun 2023 | - | -$13.36 M(+41.4%) | -$46.61 M(-12.4%) |
| Mar 2023 | - | -$9.44 M(-15.9%) | -$53.21 M(-6.1%) |
| Dec 2022 | -$56.65 M(+33.1%) | -$11.23 M(-10.7%) | -$56.65 M(-0.6%) |
| Sep 2022 | - | -$12.57 M(-37.0%) | -$57.00 M(+7.8%) |
| Jun 2022 | - | -$19.96 M(+54.8%) | -$52.86 M(+25.9%) |
| Mar 2022 | - | -$12.89 M(+11.3%) | -$41.97 M(-1.4%) |
| Dec 2021 | -$42.56 M(+13.5%) | -$11.58 M(+37.3%) | -$42.56 M(+8.3%) |
| Sep 2021 | - | -$8.43 M(-7.0%) | -$39.30 M(+5.9%) |
| Jun 2021 | - | -$9.07 M(-32.7%) | -$37.11 M(+4.2%) |
| Mar 2021 | - | -$13.48 M(+62.1%) | -$35.61 M(-5.0%) |
| Dec 2020 | -$37.49 M(-16.7%) | -$8.32 M(+33.3%) | -$37.49 M(-7.2%) |
| Sep 2020 | - | -$6.24 M(-17.7%) | -$40.40 M(-4.9%) |
| Jun 2020 | - | -$7.58 M(-50.7%) | -$42.48 M(-11.0%) |
| Mar 2020 | - | -$15.36 M(+36.8%) | -$47.72 M(+6.1%) |
| Dec 2019 | -$44.99 M(+49.4%) | -$11.23 M(+35.0%) | -$44.99 M(+7.8%) |
| Sep 2019 | - | -$8.31 M(-35.1%) | -$41.75 M(+1.4%) |
| Jun 2019 | - | -$12.82 M(+1.4%) | -$41.17 M(+18.8%) |
| Mar 2019 | - | -$12.64 M(+58.3%) | -$34.66 M(+15.1%) |
| Dec 2018 | -$30.12 M | -$7.98 M(+3.2%) | -$30.12 M(+10.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$7.74 M(+22.7%) | -$27.17 M(+12.6%) |
| Jun 2018 | - | -$6.31 M(-22.1%) | -$24.14 M(+4.3%) |
| Mar 2018 | - | -$8.09 M(+60.9%) | -$23.14 M(+20.2%) |
| Dec 2017 | -$19.25 M(+27.0%) | -$5.03 M(+6.9%) | -$19.25 M(+6.2%) |
| Sep 2017 | - | -$4.71 M(-11.4%) | -$18.13 M(+7.1%) |
| Jun 2017 | - | -$5.31 M(+26.5%) | -$16.92 M(+13.8%) |
| Mar 2017 | - | -$4.20 M(+7.4%) | -$14.87 M(-1.9%) |
| Dec 2016 | -$15.16 M(+61.3%) | -$3.91 M(+11.6%) | -$15.16 M(+6.3%) |
| Sep 2016 | - | -$3.50 M(+7.6%) | -$14.26 M(+4.3%) |
| Jun 2016 | - | -$3.26 M(-27.5%) | -$13.67 M(+13.5%) |
| Mar 2016 | - | -$4.49 M(+49.4%) | -$12.04 M(+28.1%) |
| Dec 2015 | -$9.40 M(+96.2%) | -$3.01 M(+3.1%) | -$9.40 M(+17.4%) |
| Sep 2015 | - | -$2.92 M(+78.6%) | -$8.01 M(+26.9%) |
| Jun 2015 | - | -$1.63 M(-11.5%) | -$6.31 M(+13.2%) |
| Mar 2015 | - | -$1.85 M(+14.3%) | -$5.57 M(+16.3%) |
| Dec 2014 | -$4.79 M(+180.7%) | -$1.61 M(+32.7%) | -$4.79 M(+26.8%) |
| Sep 2014 | - | -$1.22 M(+36.0%) | -$3.78 M(+22.8%) |
| Jun 2014 | - | -$894.50 K(-15.9%) | -$3.08 M(+24.4%) |
| Mar 2014 | - | -$1.06 M(+77.0%) | -$2.47 M(+44.9%) |
| Dec 2013 | -$1.71 M(+119.4%) | -$601.10 K(+16.3%) | -$1.71 M(+54.4%) |
| Sep 2013 | - | -$516.70 K(+77.7%) | -$1.11 M(+87.8%) |
| Jun 2013 | - | -$290.70 K(-2.4%) | -$588.70 K(+97.6%) |
| Mar 2013 | - | -$298.00 K | -$298.00 K |
| Dec 2012 | -$778.00 K(-67.5%) | - | - |
| Dec 2011 | -$2.39 M | - | - |
FAQ
- What is Aldeyra Therapeutics annual free cash flow?
- What is the all time high annual FCF for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics annual FCF year-on-year change?
- What is Aldeyra Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics quarterly FCF year-on-year change?
- What is Aldeyra Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics TTM FCF year-on-year change?
What is Aldeyra Therapeutics annual free cash flow?
The current annual FCF of ALDX is -$30.33 M
What is the all time high annual FCF for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high annual free cash flow is -$778.00 K
What is Aldeyra Therapeutics annual FCF year-on-year change?
Over the past year, ALDX annual free cash flow has changed by +$26.33 M (+46.47%)
What is Aldeyra Therapeutics quarterly free cash flow?
The current quarterly FCF of ALDX is -$7.97 M
What is the all time high quarterly FCF for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high quarterly free cash flow is $500.40 K
What is Aldeyra Therapeutics quarterly FCF year-on-year change?
Over the past year, ALDX quarterly free cash flow has changed by +$50.00 K (+0.62%)
What is Aldeyra Therapeutics TTM free cash flow?
The current TTM FCF of ALDX is -$30.67 M
What is the all time high TTM FCF for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high TTM free cash flow is -$298.00 K
What is Aldeyra Therapeutics TTM FCF year-on-year change?
Over the past year, ALDX TTM free cash flow has changed by +$11.39 M (+27.07%)